A phase II trial of low-dose nab-paclitaxel for patients with previously treated or recurrent advanced gastric cancer (OGSG1302).

Masashi Hirota,Shigeyuki Tamura,Hirokazu Taniguchi,Atsushi Takeno,Hiroshi Imamura,Junya Fujita,Jin Matsuyama,Yutaka Kimura,Junji Kawada,Motohiro Hirao,Kazuhiro Nishikawa,Kazumasa Fujitani,Yukinori Kurokawa,Daisuke Sakai,Hisato Kawakami,Toshio Shimokawa,Taroh Satoh

A phase II trial of low-dose nab-paclitaxel for patients with previously treated or recurrent advanced gastric cancer (OGSG1302).

2020

Masashi Hirota
Shigeyuki Tamura
Hirokazu Taniguchi
Atsushi Takeno
Hiroshi Imamura
Junya Fujita
Jin Matsuyama
Yutaka Kimura
Junji Kawada
Motohiro Hirao
Kazuhiro Nishikawa
Kazumasa Fujitani
Yukinori Kurokawa
Daisuke Sakai
Hisato Kawakami
Toshio Shimokawa
Taroh Satoh

350Background: Paclitaxel is a key drug in second-line chemotherapy for advanced or recurrent gastric cancer (AGC) and nanoparticle albumin-bound paclitaxel (nab-PTX) is also widely used in Japan. ...

Keywords:

Cancer
Internal medicine
Medicine
Nab-paclitaxel
Oncology
Pathology
low dose
Drug
Recurrent gastric cancer
advanced gastric cancer
Paclitaxel
previously treated
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations